Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 14/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822960 | 1.00 | FEN1 (0.36) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12822913 | 0.90 | FEN1 (0.34) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13586281 | 0.90 | FEN1 (0.34) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12716728 | 0.89 | SLC6A2 (0.34) | FEN1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL13586415 | 0.88 | FEN1 (0.34) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12716828 | 0.88 | FEN1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12822999 | 0.88 | FEN1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12822361 | 0.87 | FEN1 (0.37) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12821296 | 0.87 | FEN1 (0.37) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12821750 | 0.86 | FEN1 (0.35) | FEN1ALOX5APSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FEN1 3340/4885ALOX5AP 1673/4885SLC6A2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.